Kornimate/medical-research-clean huggingface dataset:
6-session treatment for generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: generalized anxiety disorder (gad) is a chronic condition that is characterized by excessive and uncontrollable worry and anxiety. in canada, 3 to 4% of the population suffer from gad at any point in time. these individuals have a lowered quality of life and are at risk for many medical conditions such as coronary heart disease and cancer. research suggests that both pharmacological and psychological approaches are effective for treating gad in the short-term; however, psychological treatments appear to offer the greatest long-term benefits. there exist a number of effective psychological treatments for gad, most of which fall into the category of cognitive-behavioural therapy or cbt. in the 1990s, a group of canadian investigators developed a cbt protocol for gad that included four components. data from five clinical trials suggest that one of the four components is particularly important for treatment success: experiencing uncertainty rather than avoiding it in everyday life. stated differently, learning to tolerate and deal with uncertainty appears to be the key to decreasing worry and anxiety. given this finding, the investigators have developed a new treatment that exclusively targets intolerance of uncertainty: behavioural experiments for intolerance of uncertainty or be-iu. the goal of the current proposal is to test the efficacy of be-iu (6 weekly treatment sessions) by comparing it to a waiting list (wl) control condition (6 weeks). a total of 50 participants with a primary diagnosis of gad will be randomly assigned to either be-iu or wl and will be assessed at 4 time points ranging from pre-treatment to 12-month follow-up. the conditions will be compared in terms of treatment efficacy and mechanisms. the investigators will also examine the predictors of change during the 12-months following treatment. the proposed study will produce data on the efficacy and mechanisms of a treatment for gad that is less costly, less complex and easier to disseminate than treatments that are currently available.


Eligibility criteria:
inclusion criteria: 1. at least 18 years of age; 2. principal diagnosis of gad; 3. no change in medication type or dose in 4 to 12 weeks before study entry (4 weeks for benzodiazepines, 12 weeks for antidepressants and hypnotics); 4. willingness to keep medication status stable while participating in the study; 5. no use of herbal products known to have cns effects in the 2 weeks before study entry; 6. no evidence of suicidal intent (based on clinical judgement); 7. no evidence of current substance abuse, current or past schizophrenia, bipolar disorder or organic mental disorder; 8. no current participation in other trials; 9. no concurrent psychotherapy during treatment phase of trial; 10. no evidence of anxiety symptoms due to a general medical condition based on clinical judgement (e.g., clinical hyperthyroidism, hypoglycaemia, anaemia). exclusion criteria: -

Keywords: cognitive-behavioural therapy
genoss des in patients with a high risk of ischemic events (gentle registry)

Conditions: Drug-eluting Stent; Coronary Artery Disease

Summary: this is a prospective cohort study to evaluate the long-term effect and safety of genoss drug-eluting stents (des) in patients with coronary artery disease with high ischemic features.

it is known that ischemic events after percutaneous coronary intervention (pci) or coronary artery bypass surgery (cabg) increase as the anatomical, physiological, or functional complexity of coronary artery disease increases. recently, the concept of complex higher-risk and clinically indented procedure (chip) has been proposed, which includes patients with various medical conditions, patients with various heart conditions, and patients with technically complex pci. until now, genoss stents have no data on the evaluation of stents in patients with coronary artery disease and high ischemic features.

Eligibility criteria:
inclusion criteria: * subject is ≥ 19 years * subject has signed informed consent for data release exclusion criteria: * subject did not sign informed consent for data release * known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for pci, cobalt chromium, sirolimus or contrast media * pregnancy * subject with life expectancy less than 12 months * subject with cardiogenic shock
study of cabergoline in treatment of corticotroph pituitary tumor

Conditions: Cushing's Disease; Corticotroph Adenoma

Summary: this study was designed to check the efficacy of a new oral medical drug treatment, namely cabergoline, for the treatment of cushing disease due to pituitary adenoma. background: cabergoline is a dopamine 2 receptor agonist. corticotroph adenoma has shown to have the d2 receptor in in vitro studies.


Eligibility criteria:
inclusion criteria: * patient with cushing's disease uncured biochemically after pituitary surgery with adenoma on histopathology exclusion criteria: * patient's intolerance to drug or known sensitivity to ergot derivatives * pregnancy, lactation or female wishing to be pregnant * any serious medical illness * patient on any drugs known to have an interaction with cabergoline including antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc

Keywords: cabergoline
evaluation of tangible boost for patients with stevens johnson syndrome, sjogren's syndrome, and graft vs host disease

Conditions: Stevens-Johnson Syndrome; Graft Versus Host Disease in Eye; Sjogren's Syndrome; Dry Eye

Summary: the goal of this research is to determine if the tangible boost system adequately replenishes the hydra-peg coating on the surface of a rigid contact lens. hydra-peg is a coating for soft and rigid contact lens, primarily composed of polyethylene glycol-based hydrogel, which is covalently bound to the surface of a contact lens. the hydra-peg coating is intended to improve wettability and comfort with contact lenses and is currently fda approved on a number of contact lenses. for patients with stevens johnson syndrome (sjs) (ss), or graft versus host disease (gvhd), diminished efficacy of the hydra-peg coating can lead to significant decline in satisfaction with the lenses over time. this is a prospective study to evaluate the efficacy of tangible boost, a monthly conditioning solution, to replenish the hydra-peg coating on rigid gas permeable contact lenses for patients with sjs, gvhd, and ss. outcomes from this patient population will be compared to patients with dry eye disease.


Eligibility criteria:
inclusion criteria: * written informed consent has been obtained prior to any study-related procedures taking place * written documentation has been obtained in accordance with the relevant county and local privacy requirements, where applicable * male or female * 18 years of age and older prior to the initial visit * is a new or established wearer of prose lenses with optimized lens fit prior to enrollment in the study * has been diagnosed with dry eye syndrome, sjs, ss, or gvhd * in the opinion of the investigator, the subject has the ability to follow study instructions * in the opinion of the investigator, the subject has the ability to complete all study procedures and visits exclusion criteria: * aphakic (i.e., missing their natural lens inside the eye) * is currently participating in any other type of eye-related clinical or research study * is pregnant or nursing as reported by the subject * has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study. * has a known and self-reported allergy to the following substances: polyethylene glycol, polyvinyl alcohol, triethanolamine, polyquaternium-1, or edetate disodium, which are components of the tangible boost and hydra-peg systems or care regimen. * has had previous ocular surgery within the past 12 weeks * adults unable to consent (including adults unable to read and understand english) * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners * employees of bostonsight

Keywords: contact lens care
using serious game technology to improve sensitivity to eye gaze in autism

Conditions: Autism

Summary: the investigators hypothesize that this serious game (designed to provide a learning environment that maximizes opportunities for adolescents with autism to discover the functional utility of eye gaze) will improve sensitivity to eye gaze cues, specifically to identify gazed-at objects, and will also lead to increased social attention to faces in adolescents with autism. the investigators will test this hypothesis in a small-scale exploratory randomized control trial that will include both behavioral and eye tracking outcome measures.


Eligibility criteria:
inclusion criteria: 1. parent/caregiver of an adolescent with a diagnosis of asd, 2. parent/caregiver and adolescent with asd both native english speakers, 3. adolescent with asd aged between 10-18 years at enrollment, 4. adolescent has normal vision and hearing with correction as indicated by parent report, 5. adolescent is able to use a computer for the purposes of game play, 6. adolescent scores \> 80% correct (i.e., 0.5 sd less than m of td adolescents) on online eye gaze screening task, 7. asd diagnosis of adolescent confirmed in lab via the autism diagnostic observation schedule, 8. full scale iq of adolescent determined to be between 70-130 on the kaufman brief intelligence test, 9. reading ability of adolescent determined to be at least a second grade level as assessed by the oral and written language scales, 10. adolescent is capable of cooperating with testing, 11. parent/caregiver and adolescent both consent/assent to participate in the research. exclusion criteria 1. adolescent has had seizures within the previous two years, 2. family lacks stable home internet, 3. parent or adolescent refuses to consent/assent to take part in the research, 4. adolescent is 18 and has a legal guardian, prohibiting him/her from legally consenting, or 5. adolescent is 18 and cannot understand the consent (i.e., fails consent quiz).
evaluation of valvular heart disease using cardiac ct

Conditions: Valvular Heart Disease

Summary: the evidentia registry is a multicenter study designed to evaluate valvular heart disease (vhd) using cardiac ct. it aims to assess cardiac valve anatomy, function, and myocardial characteristics through detailed ct analysis. 1. assessing the accuracy of cardiac ct in evaluating cardiac structure, volume, function, and myocardium in vhd patients. 2. comparing the severity, classification, and etiology (primary vs. functional) of vhd. 3. monitoring serial changes in vhd severity via echocardiography. 4. investigating the relationship between echocardiographic and ct-derived parameters. 5. examining the correlation between imaging findings, vhd interventions, and patient prognosis.


Eligibility criteria:
inclusion criteria: * patients with at least moderate valvular heart disease who had a cardiac ct with 64 or more rows * 18 years of age or older exclusion criteria: * less than 18 years old * acute vhd * infectious endocarditis * patients with post-vhd intervention * poor ct image quality for analyzing ct data.
the effect of aspirin on survival in in patients undergoing chronic hemodialysis

Conditions: Hemodialysis

Summary: the aim of present study is to examine the effect of low-dose aspirin on the incidence of cardiovascular events and mortality in patients undergoing chronic hemodialysis.

this study prospectively evaluate the impacts of low dose aspirin on survival and cardio-cerebral vascular events in a large cohort of chinese patients undergoing chronic hemodialysis. between january 2008, consecutive patients with hemodialysis with aspirin were enrolled.we examine the association of aspirin with all-cause mortality in patients matched by propensity scores using the kaplan-meier method and cox models in "intention-to-treat" analyses.the secondary endpoint was rate of cardio-cerebral events.

Eligibility criteria:
inclusion criteria: all patients aged 18 to 85, undergoing chronic hemodialysis, who have none of the following exclusion criteria. exclusion criteria: history of gastric or duodenal ulcers known allergy to aspirin or other nsaids -

Keywords: aspirin
a non-interventional interview study of phenylketonuria (pku) adults

Conditions: Phenylketonuria (PKU)

Summary: the 165-901 study is designed to identify the appropriate tools for use in future interventional studies on the neurocognitive effects of pegvaliase on adults with pku.

clinical studies have suggested that treatment with pegvaliase results in lowering of blood phenylalanine levels in adults with phenylketonuria (pku). because these individuals often exhibit inattention and mood difficulties, and blood phe concentration affects cognition and mood, life-long blood phe control with pegvaliase may improve cognitive abilities and emotional and mental health in patients with pku. in order to adequately quantify potential pegvaliase treatment impact on cognition and mood, it is necessary to employ clinical outcome assessments (coas) that are fit for purpose and that comprehensively address concepts important, relevant, and meaningful to pku patients. this is an observational study to identify symptom, function, and health-related quality of life (hrqol) concepts of interest (cois) to patients with pku and to seek additional patient, observer, and expert input on the appropriateness of concepts of biomarin's proposed coas for use in future efficacy trials in pku.

Eligibility criteria:
inclusion criteria: patients eligible to participate in this study must meet all of the following criteria: 1. ≥18 and ≤70 years of age at the time of consent; 2. clinically-confirmed diagnosis of phenylketonuria (pku); 3. blood phe test completed within eight weeks prior to screening date or blood phe test completed within eight weeks post screening date; 4. able to read, understand, and speak fluently the language(s) of their designated country sufficiently to participate in an interview and/or complete all assessments; 5. willing and able to participate in a telephone interview lasting approximately 90 minutes; 6. willing to be audio-recorded during the interview session; 7. willing and able to provide written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate. exclusion criteria: patients meeting any of the following criteria will not be included in the study: 1. currently pregnant; 2. current or previous exposure to pegvaliase treatment or participation in a pegvaliase clinical trial; 3. has a significant cognitive impairment, hearing difficulty, visual impairment, acute psychopathology, medical condition, or insufficient knowledge of the interview language that, in the opinion of the investigator or interviewer, would interfere with his or her ability to provide written consent and participate/complete an interview.
cognitive behavior therapy for atopic dermatitis

Conditions: Atopic Dermatitis

Summary: atopic dermatitis is an inflammatory skin disease characterized by itching, dry skin and recurrent inflammatory eczema. it is one of the most common skin diseases and is associated with reduced quality of life, functional impairment and sleep difficulties. the present study aims to investigate a new exposure-based cognitive behavioral psychological treatment for the disorder. the trial is a small scale open trial (n=25) with assessments at baseline, post-treatment and 6-month follow-up. the primary outcome is the scorad.

atopic dermatitis (ad)is an inflammatory skin disease characterized by itching, dry skin and recurrent inflammatory eczema. it is one of the most common skin diseases and is associated with reduced quality of life, functional impairment and sleep difficulties. there are currently no pharmacological treatments that are effective in curing the disorder in the longer-term. itching is one of the core symptoms in ad and it has been shown that the behavioral response to itching, scratching, has a maintaining function in ad. reducing scratching may therefore play an important role in alleviating ad. although behavioral aspects play a significant role in ad only a few studies have investigated the effect of psychological treatment for ad. these studies have shown promising results and the present study aim to add to the body of knowledge by testing a new form of cognitive behavioral treatment for ad. this new treatment is based on the idea that patients could benefit from training in exposure to events that could lead to increase in itching while refraining from scratching. to enable this the treatment incorporates more recently developed cognitive behavioral components such as mindfulness training. the present study aims to investigate a new exposure-based cognitive behavioral psychological treatment for the disorder. the trial is a small scale open trial (n=25) with assessments at baseline, post-treatment and 6-month follow-up. the primary outcome is the scorad.

Eligibility criteria:
inclusion criteria: * diagnosis of ad with at least moderate severity * ad for at least 6 months * age 18-65 * ability to read and write in swedish exclusion criteria: * serious psychiatric illness * concurrent light treatment or peroral treatment for ad * pregnancy * other concurrent or recently finished psychological treatment for ad

Keywords: cognitive behavior therapy
physiological responses to maximal 4-s sprint interval cycling

Conditions: Exercise, Cardiovascular Function, Fatigue, Muscular Power

Summary: the optimal recovery duration depends on the intensity of exercise and in the present study the intensity was maximal power for 4-s while cycling an 'inertial load' ergometer (ile). recovery duration of 15, 30 and 45-s were given between 30 successive sprints.

all subjects completed an informed consent for this study that was approved by the institutional review board of the university of texas at austin. study overview. a randomized, cross-over experimental design was conducted. each participant visited the laboratory on four occasions which were separated by two to five days. measurement of body mass, familiarization with experimental procedures and cycling peak oxygen consumption test (vo2peak) were performed on the first visit. participants took part in inertial-load exercise (ile) on the remaining test days. on each separate session, a different inter-sprint recovery duration was employed (i.e. 15, 30 or 45-s). cycling power output, pulmonary gas exchange, vastus lateralis de-oxygenation status, heart rate and blood lactate were measured.

Eligibility criteria:
inclusion criteria: * healthy participants exclusion criteria: * unhealthy
postoperative analgesia with local infiltration after femoral neck fracture

Conditions: Femoral Neck Fracture

Summary: reducing pain is an essential factor for early mobilization after osteosynthesis of femoral neck fractures. systemic opioids have side effects that might obstruct mobilization and induce delirium and nausea. the investigators hypothesized that wound infiltration results in reduction in systemic opioid usage and pain relief without side effects.


Eligibility criteria:
inclusion criteria: * femoral neck fracture * fracture due to low energy trauma * ability to understand danish and give informed consent * ability to walk before trauma * indication for osteosynthesis * ≥ 8 in omc (orientation-memory-concentration) test with a possible maximum of 28 points * informed consent exclusion criteria: * drug or medical abuse * drug intolerance * pathological fractures * inflammatory arthritis * patient included in the study with the contralateral hip

Keywords: femoral neck fracture hip fracture
two points versus three points turning in prevention of bed sores in critically ill patients

Conditions: Pressure Ulcer

Summary: several studies were searched the preventive measures of bed sores. although repositioning is the mainstay in most preventive measures, there is no evidence to recommend specific turning regimen. the aim of this study is to comparative the impact of the two points repositioning in lateral lying position on the right and left versus the traditional three points repositioning on the right, back, and left in the occurrence of bed sores. this study was conducted on 150 patients admitted to the critical care department of alexandria main university hospital after obtaining an informed consent from their relatives. the investigators excluded patients who: have active or healed bed sores. patients were randomly divided into two groups by allocated randomization: * group 1: traditional three points rotation. * group 2: two points rotation.

several studies were searched the preventive measures of bed sores. although repositioning is the mainstay in most preventive measures, there is no evidence to recommend specific turning regimen. aim of the study: the aim of this study was designed to evaluate the comparative impact of the two points repositioning in lateral lying position on the right and left versus the traditional three points repositioning on the right, back, and left in the occurrence of bed sores. patients: this study was conducted on 150 patients admitted to the critical care department of alexandria main university hospital after obtaining an informed consent from their relatives. the investigators excluded patients who: have active or healed bed sores. patients were randomly divided into two groups by allocated randomization: * group 1: traditional three points rotation. * group 2: two points rotation. methods: the studied patients were subjected to: complete history taking, physical examination, primary icu diagnosis, routine laboratory investigation and recording glasgaw coma scale (gcs), use of sedation, vasopressors and mechanical ventilation patients in group 1 nursed by traditional protocol \[ two hours on the right side in 30 degree lateral position, two hours on the back and two hours on the left side in 30 degree lateral position\] patients in group 2 nursed in lateral position with 30 degree two hours on the right and two hours on the left with elevation of the head of bed by 30 degree in the two groups. both groups were monitored for bed sores incidence, timing and sites of occurence

Eligibility criteria:
inclusion criteria: * patients admitted to critical care medicine department and expected to have long stay exclusion criteria: * active or healed bed sores

Keywords: pressure ulcer positioning